Global Home - Our scientific culture - Therapeutic focus

Our therapeutic focus

We focus on providing products that combat life threatening infections and offer a wide range of solutions to fight antimicrobial resistance.

Antibiotics have saved millions of lives worldwide but some drugs are losing their effectiveness due to AMR (antimicrobial resistance). This means there are fewer, or sometimes no effective treatments available for infections caused by multi-drug resistant microbes.

AMR infections claim thousands of lives each year. Many of us are now familiar with methicillin-resistant staphylococcus aureus (MRSA), which causes deadly skin infections, and carbapenem-resistant enterobacteriaceae (CRE), which can kill up to 50 percent of the people it infects. It is  paramount that we make use of existing antibiotics to help patients.

“Xellia’s global R&D growth strategy is rooted in a culture of innovation with a deep understanding of the ever changing regulatory and business environment. Our R&D team is dedicated to providing innovative solutions and pharmaceutical technology excellence to extend the utility of our core products as well as develop differentiated anti-infective treatments.”

Dr. Aleksandar Danilovski Chief Scientific Officer

Some of the infections our products treat

Bloodstream infections (Bacteremia; Septicemia)

Bacteremia is the presence of viable bacteria in the circulating blood. In some cases, bacteremia leads to sepsis and septic shock, a serious and often life-threatening condition. The most common pathogens causing bacteremia are staphylococcus aureus, which are often easily treated. However, methicillin-resistant staphylococcus aureus is multi-drug resistant, and therefore extremely difficult to treat.

SSSI (Skin and skin structure infection) and cSSSI (complicated SSSI)

SSSIs include infections of skin, subcutaneous tissue, fascia, and muscle. It encompasses a wide spectrum of clinical presentations, ranging from simple cellulitis to rapidly progressive necrotizing fasciitis. cSSSIs are among the most common infectious conditions in humans that warrant antimicrobial therapy. As most cSSSIs involve more than one type of bacteria including the anaerobic bacterial species, the choice of antimicrobials selected as empirical therapy must have broad spectrum of activity.

CF (Cystic Fibrosis)

CF is an autosomal recessive disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. People with CF develop an abnormal amount of excessively thick and sticky mucus within the lungs, airways and the digestive system. This causes impairment of the digestive functions of the pancreas and traps bacteria in the lungs resulting in recurrent infections, leading to irreversible damage. The type and severity of CF symptoms can differ widely from person to person. Therefore, although treatment plans can contain many of the same elements, they are tailored to each individual's unique circumstance.

Invasive aspergillosis

Aspergillosis is a disease caused by Aspergillus; a common mold that lives indoors and outdoors. Most people breathe in Aspergillus spores every day without getting sick. However, people with weakened immune systems or lung diseases are at a higher risk of developing health problems due to Aspergillus. Invasive aspergillosis most commonly affects the lungs, but it can also spread to other parts of the body.